Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 5/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27445055 | 0.86 | LMNA (0.46) | LMNAALDH1A1POLBHTTGLA | |
| SCHEMBL2742128 | 0.82 | ALDH1A1 (0.43) | LMNAALDH1A1POLBHTTGLA | |
| SCHEMBL132501 | 0.79 | ALDH1A1 (0.50) | LMNAALDH1A1POLBHTTGLA | |
| SCHEMBL23808381 | 0.78 | ALDH1A1 (0.41) | LMNAALDH1A1POLBHTTGLA | |
| SCHEMBL24361796 | 0.78 | GLA (0.46) | LMNAALDH1A1POLBHTTGLA | |
| SCHEMBL19007321 | 0.77 | GAA (0.37) | LMNAALDH1A1CA12CA9 | |
| SCHEMBL17693527 | 0.75 | ALDH1A1 (0.57) | ALDH1A1GLANPSR1CA12CA9 | |
| SCHEMBL3456082 | 0.73 | LMNA (0.69) | LMNAALDH1A1HTTGLANPSR1 | |
| SCHEMBL29860505 | 0.71 | ALDH1A1 (0.42) | LMNAALDH1A1POLBHTTGLA | |
| SCHEMBL16604546 | 0.70 | GAA (0.44) | LMNAALDH1A1POLBHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | LMNA 3060/4885ALDH1A1 1900/4885POLB 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.